The DOI matches its Crossref record; 69 of the 69 references it cites were found in a registry or an index.
Personality, psychopathology, life attitudes and neuropsychological performance among ritual users of ayahuasca: a longitudinal study.
Open accessAbstract
Ayahuasca is an Amazonian psychoactive plant beverage containing the serotonergic 5-HT(2A) agonist N,N-dimethyltryptamine (DMT) and monoamine oxidase-inhibiting alkaloids (harmine, harmaline and tetrahydroharmine) that render it orally active. Ayahuasca ingestion is a central feature in several Brazilian syncretic churches that have expanded their activities to urban Brazil, Europe and North America. Members of these groups typically ingest ayahuasca at least twice per month. Prior research has shown that acute ayahuasca increases blood flow in prefrontal and temporal brain regions and that it elicits intense modifications in thought processes, perception and emotion. However, regular ayahuasca use does not seem to induce the pattern of addiction-related problems that characterize drugs of abuse. To study the impact of repeated ayahuasca use on general psychological well-being, mental health and cognition, here we assessed personality, psychopathology, life attitudes and neuropsychological performance in regular ayahuasca users (n = 127) and controls (n = 115) at baseline and 1 year later. Controls were actively participating in non-ayahuasca religions. Users showed higher Reward Dependence and Self-Transcendence and lower Harm Avoidance and Self-Directedness. They scored significantly lower on all psychopathology measures, showed better performance on the Stroop test, the Wisconsin Card Sorting Test and the Letter-Number Sequencing task from the WAIS-III, and better scores on the Frontal Systems Behavior Scale. Analysis of life attitudes showed higher scores on the Spiritual Orientation Inventory, the Purpose in Life Test and the Psychosocial Well-Being test. Despite the lower number of participants available at follow-up, overall differences with controls were maintained one year later. In conclusion, we found no evidence of psychological maladjustment, mental health deterioration or cognitive impairment in the ayahuasca-using group.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“It has been repeatedly found that ingestion of a psychedelic drug can induce rapid and persisting changes in personality traits, and particularly reductions in neuroticism, in both healthy and clinical populations (24, 35–41).”
From Decreases in State and Trait Anxiety Post-psilocybin: A Naturalistic, Observational Study Among Retreat Attendees (2022) · cites this paper as [35]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Ayahuasca also displays potential mental health protection (Bouso et al., 2012; Grob et al., 1996; Halpern et al., 2008)”
From Psychological variables implied in the therapeutic effect of ayahuasca: A contextual approach (2018) · cites this paper as Bouso et al., 2012
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Bouso et al. (2012) found higher scores for spiritual orientation and purpose in life in ayahuasca users”
From Psychological variables implied in the therapeutic effect of ayahuasca: A contextual approach (2018) · cites this paper as Bouso et al. (2012)
The cited source says what the claim attributes to it.
In the citing paper
“Another study comparing personality traits between long-term ayahuasca users and non-users showed higher scores in the former of 'Self-transcendence' (Bouso et al., 2012)”
From Psychological variables implied in the therapeutic effect of ayahuasca: A contextual approach (2018) · cites this paper as Bouso et al., 2012
The cited source says what the claim attributes to it.
In the citing paper
“differences in life purpose and related variables in long-term ayahuasca users (Barbosa et al., 2016; Bouso et al., 2012).”
From Psychological variables implied in the therapeutic effect of ayahuasca: A contextual approach (2018) · cites this paper as Bouso et al., 2012
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
An Integrative Theory of Prefrontal Cortex Function
Miller, E. K., & Cohen, J. D. (2001) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.24.1.167 · Cited by 12,803
A compendium of neuropsychological tests: administration, norms, and commentary
(1991) · Choice Reviews Online · doi:10.5860/choice.29-2400 · Cited by 6,118
A psychobiological model of temperament and character
Cloninger, C. R. (1993) · Archives of General Psychiatry · doi:10.1001/archpsyc.1993.01820240059008 · Cited by 5,458
A Compendium of Neuropsychological Tests: Administration, Norms, and Commentary
Levin, H. S. (1993) · Archives of Neurology · doi:10.1001/archneur.1993.00540050007005 · Cited by 4,796
Wechsler Adult Intelligence Scale--Third Edition
Wechsler, D. (2019) · PsycTESTS Dataset · doi:10.1037/t49755-000 · Cited by 2,327
The temperament and character inventory (TCI) : a guide to its development and use
Cloninger, C. R. (1994) · Medical Entomology and Zoology · Cited by 2,319
Verdejo‐García, A., Lawrence, A. J., & Clark, L. (2008) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2007.11.003 · Cited by 1,502
Frontal–subcortical neuronal circuits and clinical neuropsychiatry
Tekin, S., & Cummings, J. L. (2002) · Journal of Psychosomatic Research · doi:10.1016/s0022-3999(02)00428-2 · Cited by 1,240
Nichols, D. E. (2004) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2003.11.002 · Cited by 1,211
Stenner, K. (2005) · Cambridge University Press eBooks · doi:10.1017/cbo9780511614712 · Cited by 942
Research works printed but not linked: 3
- [32]Bouso JC, Riba J (2011) An overview of the literature on the pharmacology and neuropsychiatric long term effects of ayahuasca. In: Santos R.G. (Ed.): The ethnopharmacology of ayahuasca. Kerala, India: Transworld Research Network. pp: 55–63. Ebook. Available: http://www.trnres.com/ebook/uploads/rafael/T_12998350813%20Rafael.pdf. Accessed: 2012 March 2.
- [35]Fuentes D, Tavares H, Camargo CHP, Gorenstein C (2000) Inventário de Temperamento e de Carácter de Cloninger – Validação da versão em Português. In: Escalas de Avaliação Clínica em Psiquiatria e Psicofarmacologia. pp. 363– 369.
- [46]Elkins DN, Hedstrom LJ, Hughes LL, Leaf JA, Saunders C (1988) Toward phenomenological spirituality: Definition, description, and measurement. J Humanist Psychol 28: 5– 18.
Cited by
Sorted by citations
Nichols, D. E. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.011478 · Cited by 1,762
Carhart-Harris, R. L., Bolstridge, M., Rucker, J., Day, C. M. J., Erritzoe, D., Kaelen, M., Bloomfield, M., Rickard, J. A., Forbes, B., Feilding, A., et al. (2016) · The Lancet Psychiatry · doi:10.1016/s2215-0366(16)30065-7 · Cited by 1,540
Psilocybin with psychological support for treatment-resistant depression: six-month follow-up
Carhart-Harris, R. L., Bolstridge, M., Day, C. M. J., Rucker, J., Watts, R., Erritzoe, D. E., Kaelen, M., Giribaldi, B., Bloomfield, M., Pilling, S., et al. (2018) · Psychopharmacology · doi:10.1007/s00213-017-4771-x · Cited by 970
Palhano-Fontes, F., Barreto, D., Onias, H., Andrade, K. C., Novaes, M. M., Pessoa, J. A., Mota-Rolim, S. A., Osório, F. L., Sanches, R., dos Santos, R. G., et al. (2019) · Psychological Medicine · doi:10.1017/s0033291718001356 · Cited by 852
Serotonin and brain function: a tale of two receptors
Carhart-Harris, R., & Nutt, D. (2017) · Journal of Psychopharmacology · doi:10.1177/0269881117725915 · Cited by 739
The Therapeutic Potential of Psychedelic Drugs: Past, Present, and Future
Carhart-Harris, R. L., & Goodwin, G. M. (2017) · Neuropsychopharmacology · doi:10.1038/npp.2017.84 · Cited by 706
Johnson, M. W., Hendricks, P. S., Barrett, F. S., & Griffiths, R. R. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.11.010 · Cited by 506
Osório, F. D. L., Sanches, R. F., Macedo, L. R., dos Santos, R. G., Maia-de-Oliveira, J. P., Wichert-Ana, L., de Araujo, D. B., Riba, J., Crippa, J. A., & Hallak, J. E. (2015) · Revista Brasileira de Psiquiatria · doi:10.1590/1516-4446-2014-1496 · Cited by 488
Psychedelics and mental health: a population study
Krebs, T. S., & Johansen, P.-Ø. (2013) · PLoS ONE · doi:10.1371/journal.pone.0063972 · Cited by 347
Adverse effects of psychedelics: From anecdotes and misinformation to systematic science
Schlag, A. K., Aday, J. S., Salam, I., Neill, J. C., & Nutt, D. (2022) · Journal of Psychopharmacology · doi:10.1177/02698811211069100 · Cited by 359
Towards an understanding of psychedelic-induced neuroplasticity
Calder, A. E., & Hasler, G. (2023) · Neuropsychopharmacology · doi:10.1038/s41386-022-01389-z · Cited by 313
dos Santos, R. G., Osório, F. L., Crippa, J. A. S., Riba, J., Zuardi, A. W., & Hallak, J. E. C. (2016) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125316638008 · Cited by 306
The paradoxical psychological effects of lysergic acid diethylamide LSD
Carhart-Harris, R. L., Kaelen, M., Bolstridge, M., Williams, T. M., Williams, L. T., Underwood, R., Feilding, A., & Nutt, D. J. (2016) · Psychological Medicine · doi:10.1017/s0033291715002901 · Cited by 293
Psychedelics not linked to mental health problems or suicidal behavior: A population study
Johansen, P.-Ø., & Krebs, T. S. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881114568039 · Cited by 330
Neuropharmacology of N,N-dimethyltryptamine
Carbonaro, T. M., & Gatch, M. B. (2016) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2016.04.016 · Cited by 268
Majić, T., Schmidt, T. T., & Gallinat, J. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881114568040 · Cited by 278
Classical psychedelics for the treatment of depression and anxiety: A systematic review
Muttoni, S., Ardissino, M., & John, C. (2019) · Journal of Affective Disorders · doi:10.1016/j.jad.2019.07.076 · Cited by 256
The therapeutic potentials of Ayahuasca: possible effects against various diseases of civilization
Frecska, E., Bokor, P., & Winkelman, M. (2016) · Frontiers in Pharmacology · doi:10.3389/fphar.2016.00035 · Cited by 242
Modern clinical research on LSD
Liechti, M. E. (2017) · Neuropsychopharmacology · doi:10.1038/npp.2017.86 · Cited by 236
Psychedelics in Psychiatry: Neuroplastic, Immunomodulatory, and Neurotransmitter Mechanisms
Inserra, A., De Gregorio, D., & Gobbi, G. (2021) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000056 · Cited by 232
Psychedelics, personality and political perspectives.
Nour, M. M., Evans, L., & Carhart-Harris, R. L. (2017) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2017.1312643 · Cited by 226
Bouso, J. C., Palhano-Fontes, F., Rodríguez-Fornells, A., Ribeiro, S., Sanches, R., Crippa, J. A. S., Hallak, J. E. C., de Araujo, D. B., & Riba, J. (2015) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2015.01.008 · Cited by 218
Uthaug, M. V., van Oorsouw, K., Kuypers, K. P. C., van Boxtel, M., Broers, N. J., Mason, N. L., Toennes, S. W., Riba, J., & Ramaekers, J. G. (2018) · Psychopharmacology · doi:10.1007/s00213-018-4988-3 · Cited by 212
Soler, J., Elices, M., Franquesa, A., Barker, S., Friedlander, P., Feilding, A., Pascual, J. C., & Riba, J. (2016) · Psychopharmacology · doi:10.1007/s00213-015-4162-0 · Cited by 209
Clinical applications of hallucinogens: a review
Garcia-Romeu, A., Kersgaard, B., & Addy, P. H. (2016) · Experimental and Clinical Psychopharmacology · doi:10.1037/pha0000084 · Cited by 201
Kettner, H., Rosas, F. E., Timmermann, C., Kärtner, L., Carhart-Harris, R. L., & Roseman, L. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.623985 · Cited by 221
Hamill, J., Hallak, J. E. C., Dursun, S. M., & Baker, G. B. (2018) · Current Neuropharmacology · doi:10.2174/1570159x16666180125095902 · Cited by 201
Effects of N,N-Dimethyltryptamine on Rat Behaviors Relevant to Anxiety and Depression
Cameron, L. P., Benson, C. J., Dunlap, L. E., & Olson, D. E. (2018) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00134 · Cited by 171
Cameron, L. P., Benson, C. J., DeFelice, B. C., Fiehn, O., & Olson, D. E. (2019) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00692 · Cited by 168
SANTOS, R. G. D., Osório, F. D. L., Crippa, J. A. S., & Hallak, J. E. C. (2016) · Brazilian Journal of Psychiatry · doi:10.1590/1516-4446-2015-1701 · Cited by 175
Legal highs: staying on top of the flood of novel psychoactive substances
Baumeister, D., Tojo, L. M., & Tracy, D. K. (2015) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125314559539 · Cited by 162
Kettner, H., Gandy, S., Haijen, E. C. H. M., & Carhart-Harris, R. L. (2019) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph16245147 · Cited by 171
Loizaga-Velder, A. K., & Verres, R. (2014) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2013.873157 · Cited by 157
Psychedelic medicine: a re-emerging therapeutic paradigm
Tupper, K. W., Wood, E., Yensen, R., & Johnson, M. W. (2015) · Canadian Medical Association Journal · doi:10.1503/cmaj.141124 · Cited by 187
Ayahuasca’s ‘afterglow’: improved mindfulness and cognitive flexibility in ayahuasca drinkers
Murphy-Beiner, A., & Soar, K. (2020) · Psychopharmacology · doi:10.1007/s00213-019-05445-3 · Cited by 135
Sub-Acute Effects of Psilocybin on Empathy, Creative Thinking, and Subjective Well-Being
Mason, N. L., Mischler, E., Uthaug, M. V., & Kuypers, K. P. C. (2019) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2019.1580804 · Cited by 172
Short term changes in the proteome of human cerebral organoids induced by 5-MeO-DMT
Dakic, V., Minardi Nascimento, J., Costa Sartore, R., Maciel, R. D. M., de Araujo, D. B., Ribeiro, S., Martins-de-Souza, D., & Rehen, S. K. (2017) · Scientific Reports · doi:10.1038/s41598-017-12779-5 · Cited by 134
Serotonergic psychedelics and personality: A systematic review of contemporary research
Bouso, J. C., dos Santos, R. G., Alcázar-Córcoles, M. Á., & Hallak, J. E. C. (2018) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2018.02.004 · Cited by 134
dos Santos, R. G., Balthazar, F. M., Bouso, J. C., & Hallak, J. E. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116652578 · Cited by 125
Classical hallucinogens as antidepressants? A review of pharmacodynamics and putative clinical roles
Baumeister, D., Barnes, G. L., Giaroli, G., & Tracy, D. K. (2014) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125314527985 · Cited by 127
Adverse effects of ayahuasca: Results from the Global Ayahuasca Survey
Bouso, J. C., Andión, Ó., Sarris, J. J., Scheidegger, M., Tófoli, L. F., Opaleye, E. S., Schubert, V., & Perkins, D. (2022) · PLOS Global Public Health · doi:10.1371/journal.pgph.0000438 · Cited by 118
Self-citationBrito-da-Costa, A. M., Dias-da-Silva, D., Gomes, N. G. M., Dinis-Oliveira, R. J., & Madureira-Carvalho, Á. (2020) · Pharmaceuticals · doi:10.3390/ph13110334 · Cited by 117
Dark Classics in Chemical Neuroscience:N,N-Dimethyltryptamine (DMT)
Cameron, L. P., & Olson, D. E. (2018) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00101 · Cited by 128
dos Santos, R. G., & Hallak, J. E. C. (2020) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2019.12.001 · Cited by 111
Jiménez-Garrido, D. F., Gómez-Sousa, M., Ona, G., Dos Santos, R. G., Hallak, J. E. C., Alcázar-Córcoles, M. Á., & Bouso, J. C. (2020) · Scientific Reports · doi:10.1038/s41598-020-61169-x · Cited by 110
Psychedelic Microdosing: Prevalence and Subjective Effects
Cameron, L. P., Nazarian, A., & Olson, D. E. (2020) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2020.1718250 · Cited by 110
Galvão, A. C. D. M., de Almeida, R. N., Silva, E. A. D. S., Freire, F. A. D. M., Palhano-Fontes, F., Onias, H., Arcoverde, E., Maia‐de‐Oliveira, J. P., de Araújo, D. B., Soares, B. L., et al. (2018) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2018.00185 · Cited by 110
Kavenská, V., & Simonová, H. (2015) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2015.1094590 · Cited by 108
Psychological and neuropsychological assessment of regular hoasca users
Barbosa, P. C. R., Strassman, R. J., da Silveira, D. X., Areco, K., Hoy, R., Pommy, J., Thoma, R., & Bogenschutz, M. (2016) · Comprehensive Psychiatry · doi:10.1016/j.comppsych.2016.09.003 · Cited by 105
Self-citationPic‐Taylor, A., da Motta, L. G., de Morais, J. A., Melo, W., Santos, A. D. F. A., Campos, L. A., Mortari, M. R., von Zuben, M. V., & Caldas, E. D. (2015) · Behavioural Processes · doi:10.1016/j.beproc.2015.05.004 · Cited by 102
Does Psychedelic Therapy Have a Transdiagnostic Action and Prophylactic Potential?
Kočárová, R., Horáček, J., & Carhart-Harris, R. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.661233 · Cited by 96
Bouso, J. C., Fábregas, J. M., Antonijoan, R. M., Rodríguez-Fornells, A., & Riba, J. (2013) · Psychopharmacology · doi:10.1007/s00213-013-3167-9 · Cited by 96
Nunes, A. A., SANTOS, R. G. D., Osório, F. D. L., Sanches, R. F., Crippa, J. A. S., & Hallak, J. E. C. (2016) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2016.1188225 · Cited by 95
Bender, D., & Hellerstein, D. J. (2022) · Psychopharmacology · doi:10.1007/s00213-021-06049-6 · Cited by 88
Safety and Side Effects of Ayahuasca in Humans—An Overview Focusing on Developmental Toxicology
SANTOS, R. G. D. (2013) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2013.763564 · Cited by 94
Kiraga, M. K., Mason, N. L., Uthaug, M. V., van Oorsouw, K. I. M., Toennes, S. W., Ramaekers, J. G., & Kuypers, K. P. C. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.721537 · Cited by 85
Lawn, W., Hallak, J. E. C., Crippa, J. A. S., SANTOS, R. G. D., Porffy, L., Barratt, M. J., Ferris, J., WINSTOCK, A. R., & Morgan, C. J. A. (2017) · Scientific Reports · doi:10.1038/s41598-017-14700-6 · Cited by 83
Perkins, D., Schubert, V., Šimonová, H., Tófoli, L. F., Bouso, J. C., Horák, M., Coelho, N. L. G., & Sarris, J. J. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.623979 · Cited by 77
Ona, G., Kohek, M., Massaguer, T., Gomariz, A., Jiménez, D. F., Dos Santos, R. G., Hallak, J. E. C., Alcázar-Córcoles, M. Á., & Bouso, J. C. (2019) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2019.1567961 · Cited by 76
Therapeutic potential of ayahuasca in grief: a prospective, observational study
González, D., Cantillo, J., Pérez, I., Farré, M., Feilding, A., Obiols, J. E., & Bouso, J. C. (2020) · Psychopharmacology · doi:10.1007/s00213-019-05446-2 · Cited by 75
Self-citationvan Oorsouw, K., Toennes, S. W., & Ramaekers, J. G. (2022) · Psychopharmacology · doi:10.1007/s00213-021-06046-9 · Cited by 74
Positive psychology in the investigation of psychedelics and entactogens: a critical review
Jungaberle, H., Thal, S., Zeuch, A., Rougemont-Bücking, A., von Heyden, M., Aicher, H., & Scheidegger, M. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.06.034 · Cited by 70
New World Tryptamine Hallucinogens and the Neuroscience of Ayahuasca
McKenna, D. J., & Jordi Riba, A. (2016) · Current topics in behavioral neurosciences · doi:10.1007/7854_2016_472 · Cited by 69
SANTOS, R. G. D., & Hallak, J. E. C. (2016) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2016.1260189 · Cited by 66
Gandy, S., Forstmann, M., Carhart-Harris, R. L., Timmermann, C., Luke, D. P., & Watts, R. (2020) · Health Psychology Open · doi:10.1177/2055102920978123 · Cited by 70
Brazilian scientific articles on “Spirituality, Religion and Health”
Damiano, R. F., Costa, L. A., Viana, M. T. S. A., Moreira-Almeida, A., Lucchetti, A. L. G., & Lucchetti, G. (2016) · Archives of Clinical Psychiatry (São Paulo) · doi:10.1590/0101-60830000000073 · Cited by 61
Examining changes in personality following shamanic ceremonial use of ayahuasca
Weiss, B., Miller, J. D., Carter, N. T., & Keith Campbell, W. (2021) · Scientific Reports · doi:10.1038/s41598-021-84746-0 · Cited by 86
Chemical composition of traditional and analog Ayahuasca
Kaasik, H., Souza, R. C. Z., Zandonadi, F. S., Tófoli, L. F., & Sussulini, A. (2021) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2020.1815911 · Cited by 59
Psychological variables implied in the therapeutic effect of ayahuasca: A contextual approach
Franquesa, A., Sainz-Cort, A., Gandy, S., Soler, J., Alcázar-Córcoles, M. Á., & Bouso, J. C. (2018) · Psychiatry Research · doi:10.1016/j.psychres.2018.04.012 · Cited by 58
Mendes, F. R., Costa, C. D. S., Wiltenburg, V. D., Morales-Lima, G., Fernandes, J. A. B., & Filev, R. (2022) · Addiction Neuroscience · doi:10.1016/j.addicn.2022.100025 · Cited by 67
A Psychoanalytic Perspective on Psychedelic Experience
Guss, J. R. (2022) · Psychoanalytic Dialogues · doi:10.1080/10481885.2022.2106140 · Cited by 61
Modulatory effects of ayahuasca on personality structure in a traditional framework
Netzband, N., Ruffell, S., Linton, S., Tsang, W., & Wolff, T. J. (2020) · Psychopharmacology · doi:10.1007/s00213-020-05601-0 · Cited by 56
Giovannetti, C., Garcia Arce, S., Rush, B., & Mendive, F. (2020) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2020.1789247 · Cited by 56
Ayahuasca: Uses, Phytochemical and Biological Activities
Estrella-Parra, E. A., Almanza-Pérez, J. C., & Alarcón-Aguilar, F. J. (2019) · Natural Products and Bioprospecting · doi:10.1007/s13659-019-0210-5 · Cited by 61
SANTOS, R. G. D., & Hallak, J. E. C. (2019) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2019.04.053 · Cited by 66
Luoma, J. B., Sabucedo, P., Eriksson, J., Gates, N., & Pilecki, B. C. (2019) · Journal of Contextual Behavioral Science · doi:10.1016/j.jcbs.2019.10.003 · Cited by 56
Perkins, D., Pagni, B. A., Sarris, J. J., Barbosa, P. C. R., & Chenhall, R. D. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.884703 · Cited by 63
Perkins, D., Opaleye, E. S., Šimonová, H., Bouso, J. C., Tófoli, L. F., Coelho, N. L. G., Schubert, V., & Sarris, J. J. (2021) · Drug and Alcohol Review · doi:10.1111/dar.13348 · Cited by 54
Lanaro, R., Calemi, D. B. D. A., Togni, L. R., Costa, J. L., Yonamine, M., Cazenave, S. O. S., & Linardi, A. (2015) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2015.1013202 · Cited by 52
Foldi, C. J., Liknaitzky, P., Williams, M., & Oldfield, B. J. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.00043 · Cited by 51
Magaraggia, I., Kuiperes, Z., & Schreiber, R. (2021) · Neurobiology of Learning and Memory · doi:10.1016/j.nlm.2021.107467 · Cited by 51
Psychedelic therapies reconsidered: compounds, clinical indications, and cautious optimism
Mitchell, J., & Anderson, B. T. (2023) · Neuropsychopharmacology · doi:10.1038/s41386-023-01656-7 · Cited by 55
Ayahuasca: A review of historical, pharmacological, and therapeutic aspects
Ruffell, S., Crosland‐Wood, M., Palmer, R., Netzband, N., Tsang, W., Weiss, B., Gandy, S., Cowley‐Court, T., Halman, A., McHerron, D., et al. (2023) · Psychiatry and Clinical Neurosciences Reports · doi:10.1002/pcn5.146 · Cited by 61
Psychoactive natural products: overview of recent developments.
Ujváry, I. (2014) · PubMed · doi:10.4415/ann_14_01_04 · Cited by 48
Psychedelics and virtual reality: parallels and applications
Aday, J. S., Davoli, C. C., & Bloesch, E. K. (2020) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125320948356 · Cited by 47
Psychedelics and potential benefits in “healthy normals”: A review of the literature
Gandy, S. (2019) · Journal of Psychedelic Studies · doi:10.1556/2054.2019.029 · Cited by 52
Ayahuasca's therapeutic potential: What we know – and what not
Maia, L. O., Daldegan‐Bueno, D., Wießner, I., de Araújo, D. B., & Tófoli, L. F. (2022) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2022.10.008 · Cited by 54
Mini-review: The neurobiology of treating substance use disorders with classical psychedelics
Urban, M. M., Stingl, M., & Meinhardt, M. W. (2023) · Frontiers in Neuroscience · doi:10.3389/fnins.2023.1156319 · Cited by 45
Psychedelic unselfing: self-transcendence and change of values in psychedelic experiences
Kähönen, J. (2023) · Frontiers in Psychology · doi:10.3389/fpsyg.2023.1104627 · Cited by 50
Wießner, I., Olivieri, R., Falchi-Carvalho, M., Palhano-Fontes, F., Maia, L. O., Feilding, A., de Araújo, D. B., Ribeiro, S. T. G., & Tófoli, L. F. (2022) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2022.01.114 · Cited by 41
Potential use of ayahuasca in grief therapy
González, D., Carvalho, M., Cantillo, J., Aixalá, M., & Farré, M. (2019) · OMEGA - Journal of Death and Dying · doi:10.1177/0030222817710879 · Cited by 44
Révész, D., Oña, G., Rossi, G. N., Rocha, J. M., SANTOS, R. G. D., Hallak, J. E. C., Alcázar‐Córcoles, M. Á., & Bouso, J. C. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.687546 · Cited by 47
Orłowski, P., Ruban, A., Szczypiński, J., Hobot, J., Bielecki, M., & Bola, M. (2022) · Journal of Psychopharmacology · doi:10.1177/02698811221089034 · Cited by 41
The Shipibo ceremonial use of ayahuasca to promote well-being: An observational study
Gonzalez, D., Cantillo, J., Perez, I., Carvalho, M., Aronovich, A., Farre, M., Feilding, A., Obiols, J. E., & Bouso, J. C. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.623923 · Cited by 40
N,N‐dimethyltryptamine and Amazonian ayahuasca plant medicine
James, E., Keppler, J., Robertshaw, T. L., & Sessa, B. (2022) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.2835 · Cited by 50
Apud, I., & Romaní, O. (2016) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2016.07.011 · Cited by 40
Barrett, F. S., Schlienz, N. J., Lembeck, N. A., Waqas, M., & Vandrey, R. G. (2018) · Cannabis and Cannabinoid Research · doi:10.1089/can.2017.0052 · Cited by 41
Ayahuasca and the Treatment of Drug Addiction
Bouso, J. C., & Riba, J. (2013) · Springer eBooks · doi:10.1007/978-3-642-40426-9_6 · Cited by 42
Berlowitz, I., Ghasarian, C., Walt, H., Mendive, F. M., Alvarado, V., & Martin-Söelch, C. (2017) · Brazilian Journal of Psychiatry · doi:10.1590/1516-4446-2016-2117 · Cited by 48
Rocha, J. M., Rossi, G. N., Osório, F. D. L., Bouso, J. C., Silveira, G. D. O., Yonamine, M., Crevelin, E. J., Queiroz, M. E. C., Hallak, J. E. C., & SANTOS, R. G. D. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.688439 · Cited by 36
Metadata
- Authors
- Bouso, J. C., González, D., Fondevila, S., Cutchet, M., Fernández, X., Ribeiro Barbosa, P. C., Alcázar-Córcoles, M. Á., Araújo, W. S., Barbanoj, M. J., Fábregas, J. M., & Riba, J.
- Affiliations
- Universitat Autònoma de Barcelona (ES)
- Instituto de Salud Carlos III (ES)
- Corresponding author
- Bouso, José Carlos
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2012-08-08
- Volume
- 7
- Issue
- 8
- Pages
- e42421
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC3414465
- OpenAlex
- W2100834566
- Cited by
- 313
- References
- 67
- Citations by year
- 2026: 12 · 2025: 23 · 2024: 31 · 2023: 30 · 2022: 38 · 2021: 32 · 2020: 31 · 2019: 16 · 2018: 21 · 2017: 14 · 2016: 20 · 2015: 23 · 2014: 15 · 2013: 6
- FWCI
- 15.93
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS ONE (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (publishedVersion)
- Tesis Doctorals en Xarxa (Consorci de Serveis Universitaris de Catalunya) (publishedVersion)
- Biblos-e Archivo (Universidad Autónoma de Madrid) (submittedVersion, public-domain)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Hispana (submittedVersion, other-oa)
- Topics
- Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
- Social Sciences › Health › Religion, Spirituality, and Psychology
- Social Sciences › Psychology › Social Psychology › Paranormal Experiences and Beliefs
- Keywords
- ayahuasca, ritual drug use, personality, psychopathology, life attitude, neuropsychological performance, cognitive function, psychological well-being, harm avoidance, reward dependence, self-transcendence, self-direction, Stroop task, Wisconsin Card Sorting Test, Frontal Systems Behavior Scale, spiritual orientation, meaning of life, psychosocial well-being
- MeSH terms
- Adult, Attitude, Brazil, Cerebrovascular Circulation, Ceremonial Behavior, Female, Follow-Up Studies, Humans, Longitudinal Studies, Male, Mental Health, Middle Aged, Neuropsychological Tests, Neuropsychology, Personality, Psychopathology, Reward, Case-Control Studies, Banisteriopsis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
